Cargando…
Immunotherapy Strategies Against Multiple Myeloma
Multiple myeloma is a monoclonal B-cell malignancy characterized by an accumulation of malignant plasma cells in the bone marrow, the presence of a monoclonal protein in the serum and/or urine, decreased normal immunoglobulin levels, and lytic bone disease. Patients with multiple myeloma benefit fro...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762093/ http://dx.doi.org/10.1177/1533034617743155 |
_version_ | 1783291634193006592 |
---|---|
author | Ma, Jing Li, Qian Yu, Zhen Cao, Zeng Liu, Su Chen, Lin Li, Han Gao, Shuang Yan, Tinghui Wang, Yafei Liu, Qiang |
author_facet | Ma, Jing Li, Qian Yu, Zhen Cao, Zeng Liu, Su Chen, Lin Li, Han Gao, Shuang Yan, Tinghui Wang, Yafei Liu, Qiang |
author_sort | Ma, Jing |
collection | PubMed |
description | Multiple myeloma is a monoclonal B-cell malignancy characterized by an accumulation of malignant plasma cells in the bone marrow, the presence of a monoclonal protein in the serum and/or urine, decreased normal immunoglobulin levels, and lytic bone disease. Patients with multiple myeloma benefit from combination therapy including novel therapeutic agents followed by autologous stem cell transplantation prolonged maintenance therapy. However, multiple myeloma remains incurable; most patients with multiple myeloma will eventually become resistant to chemotherapy, and progression or relapse of the disease is inevitable. Immunotherapy represents a novel therapeutic approach with few adverse effects and good targeting capability that might be a powerful pool to allow long-term control of minimal residual disease. This article reviews the literature evaluating 4 major immunotherapeutic approaches for multiple myeloma including cellular immunotherapy, humoral immunotherapy, radio immunotherapy, and immunomodulation. |
format | Online Article Text |
id | pubmed-5762093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-57620932018-01-17 Immunotherapy Strategies Against Multiple Myeloma Ma, Jing Li, Qian Yu, Zhen Cao, Zeng Liu, Su Chen, Lin Li, Han Gao, Shuang Yan, Tinghui Wang, Yafei Liu, Qiang Technol Cancer Res Treat Reviews Multiple myeloma is a monoclonal B-cell malignancy characterized by an accumulation of malignant plasma cells in the bone marrow, the presence of a monoclonal protein in the serum and/or urine, decreased normal immunoglobulin levels, and lytic bone disease. Patients with multiple myeloma benefit from combination therapy including novel therapeutic agents followed by autologous stem cell transplantation prolonged maintenance therapy. However, multiple myeloma remains incurable; most patients with multiple myeloma will eventually become resistant to chemotherapy, and progression or relapse of the disease is inevitable. Immunotherapy represents a novel therapeutic approach with few adverse effects and good targeting capability that might be a powerful pool to allow long-term control of minimal residual disease. This article reviews the literature evaluating 4 major immunotherapeutic approaches for multiple myeloma including cellular immunotherapy, humoral immunotherapy, radio immunotherapy, and immunomodulation. SAGE Publications 2017-12-26 2017-12 /pmc/articles/PMC5762093/ http://dx.doi.org/10.1177/1533034617743155 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Reviews Ma, Jing Li, Qian Yu, Zhen Cao, Zeng Liu, Su Chen, Lin Li, Han Gao, Shuang Yan, Tinghui Wang, Yafei Liu, Qiang Immunotherapy Strategies Against Multiple Myeloma |
title | Immunotherapy Strategies Against Multiple Myeloma |
title_full | Immunotherapy Strategies Against Multiple Myeloma |
title_fullStr | Immunotherapy Strategies Against Multiple Myeloma |
title_full_unstemmed | Immunotherapy Strategies Against Multiple Myeloma |
title_short | Immunotherapy Strategies Against Multiple Myeloma |
title_sort | immunotherapy strategies against multiple myeloma |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762093/ http://dx.doi.org/10.1177/1533034617743155 |
work_keys_str_mv | AT majing immunotherapystrategiesagainstmultiplemyeloma AT liqian immunotherapystrategiesagainstmultiplemyeloma AT yuzhen immunotherapystrategiesagainstmultiplemyeloma AT caozeng immunotherapystrategiesagainstmultiplemyeloma AT liusu immunotherapystrategiesagainstmultiplemyeloma AT chenlin immunotherapystrategiesagainstmultiplemyeloma AT lihan immunotherapystrategiesagainstmultiplemyeloma AT gaoshuang immunotherapystrategiesagainstmultiplemyeloma AT yantinghui immunotherapystrategiesagainstmultiplemyeloma AT wangyafei immunotherapystrategiesagainstmultiplemyeloma AT liuqiang immunotherapystrategiesagainstmultiplemyeloma |